CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms

Document Type : Research Articles

Authors

1 Clinical Pathology Department, Faulty of Medicine, Cairo University, Egypt.

2 Clinical Oncology Department (NEMROCK), Cairo University, Egypt.

3 Clinical Pathology Department, National Cancer Institute (NCI), Cairo University, Egypt.

Abstract

Background: Multiparameter flow cytometry is a useful tool for diagnostic evaluation of mature B-cell neoplasms
(MBN). Recently, it has been shown that assessment of CD200 expression may improve the distinction between
chronic lymphocytic leukemia (CLL; CD200 positive) and mantle cell lymphoma (MCL; CD200 negative), but any
potential as a prognostic marker for CLL remains to be established. Materials and methods: This cross sectional
study was conducted on sixty-seven patients newly diagnosed as having mature B-cell lymphoproliferative disorders
Levels of CD 200 in lymphoma cells were assessed. Results: CD200 was consistently expressed in CLL and hairy
cell leukemia B cells, but not in MCL cells. Heterogeneous expression was noted in other CD5 positive Non-Hodgkin
lymphomas. High CD200 expression (≥50%) was associated with a higher CD5, 19 and CD23 expression, older
age, higher TLC and absolute lymphocyte count, hepatomegaly, splenomegaly and a higher Rai stage. There were
no significant correlations between CD200 expression and response to treatment. Conclusion: CD200 could be of high
value in distinguishing CLL, MCL, and atypical CLL. CD200 expression can also be of prognostic and therapeutic
value in CLL cases.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 19, Issue 12
December 2018
Pages 3383-3392

Files

History

  • Receive Date: 06 November 2017
  • Revise Date: 28 December 2017
  • Accept Date: 04 February 2018

Share

How to cite

Statistics